Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease

Imatinib is a promising candidate for the treatment of fibrotic diseases. This retrospective study evaluated the use of imatinib for the treatment of refractory sclerotic chronic graft-versus-host disease in 14 patients with different hematologic malignancies. Imatinib was started at a median of 44...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Magro, Leonardo, Mohty, Mohamad, Catteau, Benoit, Coiteux, Valérie, Chevallier, Patrice, Terriou, Louis, Jouet, Jean-Pierre, Yakoub-Agha, Ibrahim
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2009
Assuntos:
Transplantation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5162701/
https://ncbi.nlm.nih.gov/pubmed/19289852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-02-204750
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares